Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy

Kalay, Nihat; Başar, Emrullah; Özdoğru, İbrahіm; Er, Özlem; Çetinkaya, Yakup; Doğan, Ali; İnanç, Tuğrul; Oğuzhan, Abdurrahman; Eryol, Namık Kemal; Topsakal, Ramazan; Ergin, Ali

doi:10.1016/j.jacc.2006.07.052

Cited by 627 publications

(402 citation statements)

References 26 publications

Supporting

Mentioning

347

Contrasting

Unclassified

Order By: Relevance

“…Observational studies and small randomized clinical trials suggest a benefit in early initiation of angiotensin‐converting enzyme inhibitors and beta‐blockers for the prevention of cardiotoxicity 15, 89, 90, 91, 92, 93. The PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) trial tested whether angiotensin receptor blockers and/or beta‐blockers would be effective in preventing cardiotoxicity in patients diagnosed with breast cancer receiving anthracycline‐based chemotherapy with and without trastuzumab.…”

Section: Prevention and Treatment Of Cardiotoxicity Associated With Hmentioning

confidence: 99%

Cardiotoxicity From Human Epidermal Growth Factor Receptor‐2 (HER2) Targeted Therapies

Florido

Smith

Cuomo

et al. 2017

JAHA

View full text Add to dashboard Cite

Section: Prevention and Treatment Of Cardiotoxicity Associated With Hmentioning

confidence: 99%

Cardiotoxicity From Human Epidermal Growth Factor Receptor‐2 (HER2) Targeted Therapies

Florido

Smith

Cuomo

et al. 2017

JAHA

View full text Add to dashboard Cite

“…63 Cardinale and Sandri 63 has proposed the potential role of troponin as a standard marker in identifying patients at risk of cardiotoxicity, and has advocated use of angiotensin-converting enzyme inhibitors, angiotensin II type 1a receptor blockers, and/or carvedilol 64 in preventing cardiac dysfunction and cardiac events in at risk patients. However, at this time no clarity exists as to recommended timing and guidelines for use of biomarkers and their role in modifying chemotherapy.…”

Section: Biomarkersmentioning

confidence: 99%

Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction noninvasively

Schwartz

Jain

Storozynsky

2013

Journal of Nuclear Cardiology

View full text Add to dashboard Cite

The field of cardio-oncology is challenged to address an ever greater spectrum of cardiotoxicity associated with combination chemotherapy, greater dose intensity, extremes of age, and enhanced patient survival which exposes more protracted risk of developing congestive heart failure (CHF). Recent reports of chemotherapy-induced hypertension as a common adverse effect of angiogenesis inhibitors and immunosuppressants clarify the need for routine blood pressure (BP) monitoring and guideline-based management of hypertension as an integral strategy to preserve LV function. Serial monitoring of radionuclide left ventricular ejection fraction (LVEF) in adults and echocardiography in children continues to provide outcome based, cost-effective prevention of CHF in high risk patients receiving chemotherapy. To optimize treatment and monitoring strategies to eliminate late-onset LV dysfunction and CHF, traditional and novel candidate methods for assessment of chemotherapy-induced LV dysfunction are reviewed. These include serial assessment of LV volume indices by gated SPECT ERNA and gated SPECT MPI, 3D echocardiography and contrast 2D echocardiography; longitudinal strain imaging, diastolic functional parameters, 123 I-MIBG, 111 In-Antimyosin antibody imaging, and 99m Tc-Annexin V apoptosis imaging, biomarkers including troponins and BNP; genetic markers, and both functional and tissue characterization techniques with T1 weighted and T2 weighted images with cardiac magnetic resonance imaging (CMR). In our quest to optimize strategies for long-term cancer survival and prevention of CHF for patients receiving chemotherapy, rigorous modality and guideline-specific clinical outcome trials are required. A new multi-modality monitoring approach is proposed, which integrates evidencebased strengths of CMR, echocardiography, ERNA, biomarkers, and BP management for surveillance and validation of cardiotoxicity and prevention of clinical heart failure in patients receiving a broad spectrum of cancer therapies.

show abstract

“…Меха-низм кардиопротективного действия карведилола исследователи связали с его антиоксидантной активно-стью, блокированием апоптозных сигнальных путей, кроме того обсуждалась возможность восстановления работы Ca 2+ -АТФ-азы и блокирование притока кальция в кардиомиоциты. Однако данное исследование прове-дено только на 50 пациентах (25 человек получали кар-ведилол, 25 -плацебо) [24].…”

Section: таблица 1 продолжениеunclassified

Modern View on Cardiotoxicity of Chemotherapeutics in Oncology Including Anthracyclines

Гендлин¹,

Емелина²,

Никитин³

et al. 2017

Russ J Cardiol

View full text Add to dashboard Cite

Высокая эффективность современной химиолучевой терапии позволила добиться больших успехов в лечении онкогематологических заболеваний. Основой многих схем полихимиотерапии первой линии лечения остаются антрациклиновые антибиотики. Эффективное лечение основного заболевания в ряде случаев сопровождается развитием различных осложнений со стороны сердечно-сосудистой системы, в том числе очень тяжелых, с развитием летального исхода. Необходимо учитывать возможность развития не только острой кардиотоксичности, но и различных осложнений со стороны сердечно-сосудистой системы после завершения противоопухолевого лечения. Алго-ритм подготовки пациентов к химиолучевой терапии, должен обязательно включать обследование сердечно-сосудистой системы до начала лечения, в дальнейшем необходимо регулярное обследование на протяжении терапии. Профилактика и лечение кардиотоксичности являются сложными клиниче-скими задачами в силу необратимости и прогрессирующего характера боль-шинства изменений со стороны сердечно-сосудистой системы. Важным аспектом является тесное взаимодействие кардиолога и онколога при веде-нии больных. Необходимо длительное динамическое наблюдения за пациен-тами, получавшими химиолучевую терапию для максимально ранней диагно-стики сердечно-сосудистых осложнений в отдаленном периоде после оконча-ния противоопухолевого лечения.

show abstract

Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy

Abstract: Prophylactic use of carvedilol in patients receiving ANT may protect both systolic and diastolic functions of the left ventricle.

Cited by 627 publications

References 26 publications

Cardiotoxicity From Human Epidermal Growth Factor Receptor‐2 (HER2) Targeted Therapies

Cardiotoxicity From Human Epidermal Growth Factor Receptor‐2 (HER2) Targeted Therapies

Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction noninvasively

Modern View on Cardiotoxicity of Chemotherapeutics in Oncology Including Anthracyclines

Contact Info

Product

Resources

About